Changes in Beneficial Ownership · 4
Milestone Pharmaceuticals Inc.
MISTNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-06122026_040603.xml
Filing details
- Report period
- 2026-06-10
- Issuer
- Milestone Pharmaceuticals Inc.
- Issuer CIK
- 0001408443
- Trading symbol
- MIST
Reporting owner 1
- Name
- Duty Stuart
- Reporting owner CIK
- 0001970274
- Relationship
- Director
- Address
- C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL, QUEBEC, CANADA, A8, H4M 2X6
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | 1.22 | 2026-06-10 | A · Form 4 | 77,000 | A | 0 | [F1] | 2036-06-10 | Common Stock | 77,000 | 77,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.↩ 1
Signature 1
- Signed
- /s/ Joseph Oliveto, Attorney-in-Fact
- Date
- 2026-06-12
Company context
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST® (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in Phase 3 development for the control of symptomatic episodic attacks associated with AFib-RVR. https://milestonepharma.com/
Current securities
Recent company filings
- Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingOct 28, 2026
- Other EventsSep 3, 2026
- Results of Operations and Financial ConditionAug 12, 2026
- 10-Q filingAug 12, 2026
- SCHEDULE 13G - filed by Pavaki Capital Management LLC regarding Milestone Pharmaceuticals Inc.Aug 7, 2026